Ticker: MRNA

Moderna

Pharma Healthcare Biotechnology

Price 135.02

Reco Sell Potential 41 Risk 73 Updated 2026-09-10

Official website

Forecast impact

negative

Target -40.3% target fill 167.4%

Reaction D5 +6.02% · D10 pending market trust

Impact Potential -4 · Risk +3 valid until 2026-10-03

Track in portfolio

Price chart

AI recommendation Analyst forecast Calendar event Positive signal Negative signal Neutral / update Hold / informational B My buy S My sell

Description

Company and Business Model

Moderna is a biotechnology company focused on developing messenger RNA (mRNA) therapeutics and vaccines. Its core products include the COVID-19 vaccine and various candidates for infectious diseases, cancer, and rare diseases. The company primarily generates revenue from vaccine sales, with a significant portion derived from government contracts and partnerships. Moderna's business segments include research and development, manufacturing, and commercialization of its mRNA-based products.

Investment Profile

The investment profile of Moderna is more aligned with growth investors, given its focus on innovative mRNA technology and potential future product pipeline. However, the high risk associated with its current financial performance and market volatility may deter conservative investors. The stock may appeal to those with a medium to long-term horizon who are willing to navigate potential fluctuations.

Category: Pharma Sector: Healthcare Industry: Biotechnology Investment style: Growth Horizon: Medium-term Company type: Blue Chip Company type: Market Leader Experience: Basic

Fundamental metrics (experimental) Updated: 2026-09-10

EPS (TTM) — earnings per share for the last 12 months, $: -7.98
Revenue QoQ — quarter-over-quarter revenue growth: -62.7%
EPS surprise: 60.9%
20d volatility: 39.5%

AI recommendation changes

Date	Before	After	Reason
2026-08-25	Hold	Sell	Weak fundamentals and high volatility raise significant concerns.
2026-08-23	Sell	Hold	High volatility and negative fundamentals raise concerns.
2026-08-21	Hold	Sell	scenario_deterioration
2026-08-15	Sell	Hold	Weak fundamentals and high risk limit upside potential.
2026-07-09	Hold	Sell	Weak fundamentals and negative momentum raise significant concerns.
2026-07-02	Sell	Hold	Strong recent performance, but fundamentals show weakness.
2026-06-23	Hold	Sell	Weak fundamentals and high volatility raise significant risk.
2026-06-19	Sell	Hold	Strong recent performance, but fundamentals show weakness.
2026-06-11	Hold	Sell	scenario_deterioration
2026-06-05	Sell	Hold	Weak fundamentals offset by recent price momentum.
2026-06-03	Hold	Sell	scenario_deterioration
2026-05-28	Sell	Hold	Weak fundamentals and high volatility raise concerns.
2026-05-16	Hold	Sell	scenario_deterioration
2026-05-08	—	Hold	Weak fundamentals and high volatility raise concerns.
2026-05-08	Hold	Hold	Компания Moderna демонстрирует значительный рост за последние 120 дней, однако отрицательный EPS и снижение выручки указывают на риски. Рекомендуется удерживать акции до получения более ясных сигналов о восстановлении.
2026-03-27	Sell	Hold	Компания Moderna демонстрирует сильный рост за последние 60 и 120 дней, однако отрицательный EPS и значительное снижение выручки в квартальном выражении указывают на риски. Рекомендуется удерживать акции до прояснения фи
2026-03-20	Hold	Sell	Компания испытывает значительное снижение выручки и отрицательный EPS, что указывает на финансовые проблемы. Текущая цена акций также значительно ниже недавних максимумов, что может свидетельствовать о дальнейшем падении
2026-02-08	Buy	Hold	Компания показывает сильный рост выручки и положительную динамику за последние 60 дней, что указывает на высокий потенциал. Однако отрицательный EPS и высокая волатильность требуют осторожности.
2026-01-30	Hold	Buy	Компания Moderna демонстрирует значительный рост выручки и положительную динамику акций за последние месяцы, что указывает на потенциал для дальнейшего роста. Однако отрицательный EPS и высокая волатильность требуют осто
2026-01-25	Buy	Hold	Компания Moderna демонстрирует сильный рост выручки и позитивные результаты по сюрпризам, однако отрицательный EPS и высокая волатильность акций указывают на значительные риски.

Analyst forecasts

Date	Analyst	Action	Target	Price Then
2026-09-03	UBS	Rating Downgraded	— → 81	150.81
2026-08-28	Argus Research	Update	— → 180	142.77
2026-08-24	Barclays	Target Raised	48 → 125	145.13
2026-08-20	UBS	Target Raised	50 → 150	174.38
2026-08-19	Goldman Sachs	Target Raised	67 → 120	174.38
2026-08-19	RBC Capital	Target Raised	45 → 130	151.3
2026-08-19	Loop Capital Markets	Update	— → 135	139.12
2026-08-19	D.A. Davidson	Target Lowered	— → 245	138.205
2026-07-21	Goldman Sachs	Target Raised	49 → 67	59.49
2026-07-20	Wolfe Research	Target Raised	— → 25	61.82
2026-07-08	Morgan Stanley	Target Raised	33 → 39	79.77
2026-07-07	RBC Capital	Target Raised	38 → 45	81.8
2026-06-26	Piper Sandler	Target Raised	69 → 77	67.66
2026-05-04	UBS	Target Raised	36 → 45	47.465
2026-05-04	RBC Capital	Target Raised	35 → 38	46.87
2026-05-01	Goldman Sachs	Target Raised	43 → 49	45.37
2026-05-01	Morgan Stanley	Target Raised	30 → 33	44.18
2026-03-03	Jefferies	Update	— → 37	49.83
2026-02-17	RBC Capital	Target Raised	25 → 30	42.54
2026-02-17	Evercore ISI	Target Raised	28 → 35	43.19
2026-02-17	Bernstein	Target Raised	35 → 45	42.23
2026-02-16	UBS	Target Raised	34 → 36	42.23
2026-02-16	Morgan Stanley	Target Raised	28 → 30	42.23

News Page 1 of 3

Stocks Making Significant Moves Premarket: Snowflake Surges 24%, Moderna Downgraded to Sell

09/03/2026, 05:37 AM business review Argan Petco Campbell Soup Company Ultragenyx Pharmaceutical Datadog Snowflake Moderna Broadcom Hewlett Packard Enterprise

Snowflake's shares surged 24% after exceeding earnings expectations, positively impacting its software peers, while several other companies experienced notable stock movements based on their earnings reports and forecasts.

Analysts Rothschild & Co downgraded Moderna (MRNA) to Sell while raising target price to $81, indicating potential downside of 46%

09/03/2026, 04:36 AM investing rating_drop Analysts: analysts, Rothschild & Co Moderna

Rothschild & Co has downgraded Moderna's stock to sell, citing that it is considerably overvalued despite raising its price target to $81, which still indicates a significant downside from current levels.

Jim Cramer Reviews August’s Stock Comeback Driven by Improving Fundamentals

08/31/2026, 04:36 PM economy review software finance Palantir Technologies Super Micro Computer Sandisk Newmont Gartner Coinbase Moderna Salesforce

August marked a significant recovery for stocks that had previously faced bearish pressures, with notable rebounds in companies like Moderna and various software firms, driven by improving fundamentals and a shift in investor sentiment.

Analysts Bank of America raised Affirm (AFRM) target price to $104 following earnings report

08/28/2026, 05:37 AM investing rating_growth Analysts: analysts, Bank of America Baozun TeraWulf (WULF) SpaceX Amazon Marvell Technology Affirm Holdings Nvidia Tesla Moderna

Several Wall Street firms have made significant calls on various companies, indicating potential investment opportunities and shifts in market sentiment. Notably, upgrades and reiterations from firms like Stifel, Bank of America, and CLSA highlight companies with promising growth prospects and favorable valuations.

Stocks Making Significant Moves Midday: Nvidia Surges 9%, Veeva Jumps 16%, and Celsius Downgraded by Deutsche Bank

08/27/2026, 11:38 AM business review software ai Nvidia Veeva Systems Burlington Stores Celsius Holdings Dollar Tree Okta HP Best Buy Dollar General Moderna

Several companies experienced significant stock movements due to earnings reports and guidance updates, with Nvidia and Okta showing strong gains while others like HP and Moderna faced declines due to market concerns.

Stocks Making Significant Moves Midday: Dick’s Sporting Goods Plummets, Dynatrace and Shift4 Payments Upgraded

08/25/2026, 09:38 AM business review consumer software Kura Oncology Navitas Semiconductor Advanced Micro Devices Marvell Technology Dick's Sporting Goods Shift4 Payments Moderna

Investors should note significant stock movements today, particularly Dick's Sporting Goods, which saw a dramatic decline due to disappointing revenue, while several tech and biotech companies experienced gains following upgrades and positive developments.

S&P 500 Experiences Weekly Loss Despite Surge in Overbought Stocks Including Moderna and Merck

08/22/2026, 05:31 AM investing review Estee Lauder Merck Agilent Technologies Thermo Fisher Scientific Moderna

The S&P 500 experienced a decline after three weeks of gains, primarily due to rising Treasury yields, while several individual stocks, particularly in the healthcare and cosmetics sectors, reached overbought levels following strong earnings and positive trial results.

Stocks Making Significant Moves Midday: BJ’s Wholesale, Robinhood, Coinbase, and More

08/21/2026, 09:38 AM business review InnovAge OSI Systems O-I Glass Robinhood BJ's Wholesale Club Parsons Coinbase Boston Beer Moderna Broadcom

Several companies experienced significant stock movements due to earnings reports and market developments, highlighting the impact of financial performance and regulatory news on investor sentiment.

U.S. Treasury Secretary Scott Bessent Addresses Economic Pressure on Iran Amid Bond Market Challenges

08/20/2026, 06:36 PM review finance Merck Walmart Moderna

U.S. Treasury Secretary Scott Bessent's recent comments on economic strategies regarding Iran and the U.S. budget deficit have failed to stabilize bond yields, leading to a decline in the S&P 500. This situation raises concerns about the effectiveness of government interventions in the current market environment.

Stocks Making Significant Moves Midday: Walmart, Deere, CrowdStrike, and More

08/20/2026, 10:37 AM business review Advance Auto Parts Deere & Company Coty Walmart Moderna

Walmart's disappointing sales growth and earnings guidance led to a significant drop in its stock, while Deere's strong quarterly performance resulted in a notable share price increase. These movements reflect broader trends in retail and industrial sectors, impacting investor sentiment.